首页> 外文期刊>Hypertension: An Official Journal of the American Heart Association >Impact of Intensive Versus Standard Blood Pressure Management by Tertiles of Blood Pressure in SPRINT (Systolic Blood Pressure Intervention Trial)
【24h】

Impact of Intensive Versus Standard Blood Pressure Management by Tertiles of Blood Pressure in SPRINT (Systolic Blood Pressure Intervention Trial)

机译:在SPRINT(收缩压干预试验)中,三分之二的血压对强化标准血压管理的影响

获取原文
           

摘要

Intensive systolic blood pressure (SBP) control improved outcomes in SPRINT (Systolic Blood PressureIntervention Trial). Our objective was to expand on reported findings by analysis of baseline characteristics, primaryoutcomes, adverse events, follow-up blood pressure, and medication use differences by baseline SBP (tertile 1 [T1], 145 mm Hg). Participants with higher baseline SBP tertile were moreoften women and older, had higher cardiovascular risk, and lower utilization of antihypertensive medications, statins,and aspirin. Achieved SBP in both treatment arms was slightly higher in T2 and T3 compared with T1 and fewer inthe T3 groups achieved SBP targets compared with T1 and T2 groups. The primary composite outcome with intensiveversus standard SBP treatment was reduced by 30% in T1, 23% in T2, and 17% in T3 with no evidence of an interaction(P=0.77). Event rates were lower in the intensive arm, and there was no evidence that this benefit differed by SBP tertile.There was no difference in the hazard for serious adverse events in any of the 3 tertiles. Medication utilization differedacross the SBP tertiles at baseline with a lesser percentage of diuretics and angiotensin-converting enzyme inhibitors/angiotensin receptor blocker drugs in the higher tertiles—a finding that reversed during the trial. The beneficial effectsof intensive SBP lowering were not modified by the level of baseline SBP. Within the parameters of this population,these findings add support for clinicians to treat blood pressure to goal irrespective of baseline SBP.
机译:强化收缩压(SBP)控制改善了SPRINT(收缩压干预试验)的结果。我们的目标是通过分析基线特征,主要结果,不良事件,随访血压和基线SBP(三分位数1 [T1],145 mm Hg)的用药差异,扩大报告的发现。基线SBP三分位数较高的参与者多为女性和年长者,心血管风险更高,降压药,他汀类药物和阿司匹林的使用率较低。与T1相比,两个治疗组在S2和T3中达到的SBP略高,与T1和T2组相比,在T3组中达到SBP目标的更少。强化治疗与标准SBP治疗相比,T1降低了30%,T2降低了23%,T3降低了17%,没有相互作用的证据(P = 0.77)。重症患者的事件发生率较低,并且没有证据表明SBP三分位数的益处有所不同.3个三分位数的任何三分位数中,严重不良事件的危险性均无差异。 SBP三元组的药物利用在基线时有所不同,利尿剂和血管紧张素转换酶抑制剂/血管紧张素受体阻滞剂的百分率较低,而较高的三元组中的这一百分比在试验中得到了逆转。降低SBP的有益效果并未因基线SBP的水平而改变。在此人群的参数范围内,这些发现为临床医生提供了支持,可将血压治疗至目标,而与基线SBP无关。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号